|
related topics |
{product, candidate, development} |
{stock, price, share} |
{property, intellectual, protect} |
{product, market, service} |
{interest, director, officer} |
{competitive, industry, competition} |
{stock, price, operating} |
{personnel, key, retain} |
{control, financial, internal} |
|
Risks Related to our Business and Industry
Our independent registered public accounting firm has issued an unqualified opinion with an explanatory paragraph, to the effect that there is substantial doubt about our ability to continue as a going concern.
We are a development stage company with limited operating history and our future profitability is uncertain and we anticipate future losses and negative cash flow, which may limit or delay our ability to become profitable.
If we do not receive additional financing when and as needed in the future, we may not be able to continue the research, development and commercialization of our TMOS technology and materials.
Our brand name and technology may not be recognized in our marketplace, so our results of operations and financial condition may suffer
We may fail to protect adequately our proprietary technology, which would allow our competitors to take advantage of our research and development efforts.
If we fail to enter cooperative research agreements, we might not succeed in commercializing our TMOS technology and materials.
If we cannot form and maintain lasting business relationships with flat panel display manufacturers or other targeted partners, or if we cannot obtain proprietary TMOS materials, our business strategy could suffer or fail.
The United States government will have certain rights to our TMOS technology that might prevent us from realizing the benefits of these technologies
We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.
If we are unable to keep up with rapid technological changes, our processes, products or services may become obsolete.
If our TMOS technology and materials are not technically and commercially feasible for broad-based product applications, we may never generate revenues sufficient to support ongoing operations
Our efforts may never demonstrate the feasibility of our TMOS technology and materials for broad-based product applications.
Even if our TMOS technology is technically feasible, it may not be adopted by display manufacturers
Many of our competitors have greater resources, and it may be difficult to compete against them.
The loss of the services of our key management and personnel or the failure to attract additional key personnel could adversely affect our ability to operate our business
Uni-Pixel is receiving limited indemnification from certain current and former principals of our predecessor company, Real-Estateforlease.com, Inc.
The flat panel display industry has historically experienced significant downturns, which may adversely affect the demand for and pricing of our TMOS technology and materials.
Risks Related to Owning Our Securities
Our Common Stock has traded only sporadically and is expected to experience significant price and volume volatility in the future which substantially increases the risk of loss to persons owning our Common Stock.
We are not required to meet or maintain any listing standards for our Common Stock to be quoted on the OTC Bulletin Board, which could affect our stockholders ability to access trading information about our Common Stock.
Our Common Stock may be subject to penny stock rules, which make it more difficult for our stockholders to sell their Common Stock.
We do not expect to pay dividends in the foreseeable future.
Full 10-K form ▸
|
|
related documents |
1099215--7/31/2007--PROTALEX_INC |
755806--3/1/2006--NEORX_CORP |
873303--3/16/2010--AVI_BIOPHARMA_INC |
1123979--2/14/2008--SENOMYX_INC |
799698--4/3/2006--CYTRX_CORP |
819050--3/3/2009--VICAL_INC |
819050--2/25/2010--VICAL_INC |
1396238--3/31/2010--IRIS_BIOTECHNOLOGIES_INC |
318306--5/1/2006--ACCESS_PHARMACEUTICALS_INC |
1066833--3/15/2006--DOV_PHARMACEUTICAL_INC |
1120438--3/15/2006--THIRD_WAVE_TECHNOLOGIES_INC_/WI |
849043--3/14/2006--NEUROGEN_CORP |
1114872--3/29/2006--MILLENNIUM_CELL_INC |
818033--3/31/2006--AP_PHARMA_INC_/DE/ |
1123979--2/12/2009--SENOMYX_INC |
1066833--3/30/2007--DOV_PHARMACEUTICAL_INC |
907562--3/4/2009--DYAX_CORP |
1123979--2/4/2010--SENOMYX_INC |
849043--3/15/2007--NEUROGEN_CORP |
1082278--4/9/2009--ENVIRONMENTAL_SOLUTIONS_WORLDWIDE_INC |
1082278--4/6/2010--ENVIRONMENTAL_SOLUTIONS_WORLDWIDE_INC |
879993--3/10/2006--DUSA_PHARMACEUTICALS_INC |
1314102--9/25/2009--pSivida_Corp. |
708717--10/14/2008--ALFACELL_CORP |
1023024--3/30/2010--BIOSANTE_PHARMACEUTICALS_INC |
727510--3/12/2010--ENZON_PHARMACEUTICALS_INC |
1360214--3/26/2009--TRANSDEL_PHARMACEUTICALS_INC |
895051--3/13/2009--ENTREMED_INC |
805326--3/25/2010--EMISPHERE_TECHNOLOGIES_INC |
805326--3/16/2009--EMISPHERE_TECHNOLOGIES_INC |
|